Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Snap Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.2 (market cap $29.60B), while Snap Inc trades at $5.28 (market cap $9.32B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.2× Snap Inc's market cap, and Snap Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SNAP | |
|---|---|---|
Market Cap | $29.60B | $9.32B |
Sector | Health | Media |
52-Week High | $491.22 | $9.09 |
52-Week Low | $205.48 | $3.93 |
Enterprise Value | $27.56B | $10.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Snap Inc. (SNAP) trades at $5.285, down 1.03% over 24 hours, near its analyst low target of $5.25. The stock shows a bullish technical signal with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $5.93B in 2025 with a narrowing net loss of -$460M, while Q2 2026 earnings beat expectations with 19% revenue growth. Cash flow from operations improved to $656M in 2025, signaling operational strength amid persistent losses.
Outlook remains cautious with a consensus price target of $7.02, implying 33% upside, but risks include high debt, negative profitability, and competitive pressures. Institutional sentiment is mixed with 38% buy ratings, yet insider selling and a recent downgrade to strong sell highlight volatility. Investment opportunity hinges on sustained ad revenue growth and path to profitability, balanced against execution risks in a challenging digital ad market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
